Creative Planning - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 79 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q1 2021. The put-call ratio across all filers is 1.25 and the average weighting 0.0%.

Quarter-by-quarter ownership
Creative Planning ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q3 2023$3,229
-90.3%
16,1380.0%0.00%
Q2 2023$33,244
-28.0%
16,138
+15.3%
0.00%
Q1 2023$46,174
+9.6%
13,992
-45.5%
0.00%
Q4 2022$42,117
-69.0%
25,681
-16.3%
0.00%
Q3 2022$136,000
-17.1%
30,681
-15.3%
0.00%
Q4 2020$164,000
-62.7%
36,202
+39.2%
0.00%
-100.0%
Q3 2020$440,000
+26.4%
26,002
-16.1%
0.00%0.0%
Q2 2020$348,000
+11500.0%
31,002
+3000.2%
0.00%
Q4 2016$3,000
+50.0%
1,0000.0%0.00%
Q3 2016$2,0000.0%1,0000.0%0.00%
Q2 2016$2,000
-33.3%
1,0000.0%0.00%
Q1 2016$3,0000.0%1,0000.0%0.00%
Q4 2015$3,000
+50.0%
1,0000.0%0.00%
Q3 2015$2,000
-50.0%
1,0000.0%0.00%
Q1 2015$4,0001,0000.00%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q1 2021
NameSharesValueWeighting ↓
ACUTA CAPITAL PARTNERS, LLC 2,500$825,0000.55%
SABBY MANAGEMENT, LLC 136,484$27,3100.02%
LIBERTY WEALTH MANAGEMENT LLC 352,619$710.02%
Weaver Consulting Group 99,356$19,8810.01%
ABNER HERRMAN & BROCK LLC 145,500$290.00%
JMAC ENTERPRISES LLC 65,430$13,0930.00%
Professional Financial Advisors, LLC 17,279$3,4580.00%
Ikarian Capital, LLC 90,242$18,0570.00%
MOORE CAPITAL MANAGEMENT, LP 200,000$40,0200.00%
Weaver Consulting Group 45,000$2,7500.00%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders